Q4 2024 ICON PLC Earnings Call Transcript
Key Points
- Icon PLC (ICLR) reported gross bookings of $3.06 billion in Q4, marking an 8% sequential increase and a 3% year-over-year rise.
- The company's backlog grew to $24.7 billion at the end of 2024, representing an 8.3% increase year-over-year.
- Icon PLC (ICLR) achieved a free cash flow of $1.1 billion for the full year 2024, a 10% increase over 2023.
- The company is seeing strong demand from recent strategic alliances and has several partnership opportunities beyond the top 20 pharma cohort.
- Icon PLC (ICLR) is investing in digital innovation, which has resulted in 10% faster site activation and a 24% increase in trials completed on time.
- Overall cancellations in Q4 totaled $651 million, impacting near-term revenue and margin.
- Revenue in Q4 was $2.04 billion, representing a year-on-year decrease of 1.2%.
- Adjusted EBITDA for Q4 was $423 million, a 5.7% decrease year-over-year.
- The biotech market is experiencing cautious capital allocation, with decision-making and trial start speeds not yet normalized.
- Icon PLC (ICLR) anticipates that pass-through revenue mix will increase in the first half of 2025, which will pressure EBITDA margins.
Good day, and welcome to the ICON Q4 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand you over to your speaker today, Kate Haven. Please go ahead.
Good day, and thank you for joining us on this call covering the quarter and year ended December 31, 2024. Also on the call today, we have our CEO, Dr. Steve Cutler; our CFO, Nigel Clerkin; and our COO, Barry Balfe. I would like to note that this call is webcast and that there are slides available to download on our website to accompany today's call. Certain statements in today's call will be forward-looking statements.
These statements are based on management's current expectations and information currently available, including current economic and industry conditions. Actual results may differ materially from those stated or implied by forward-looking statements due to risks and uncertainties associated with the company's business, and listeners are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
